The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV

HIV Clinical Trials

Volumn 13, Issue 1, 2012, Pages 33-45

  Opravil, Milos ^a   Rodriguez Torres, Maribel ^b   Rockstroh, Jürgen ^c   Snoeck, Eric ^d   Chung, Raymond ^e   Tietz, Andreas ^f   Torriani, Francesca ^g  

^a KLINIK HIRSLANDEN   (Switzerland)

^b Fundacion de Investigacion de Diego   (Puerto Rico)

^c UNIVERSITY OF BONN   (Germany)

^d Exprimo NV   (Belgium)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV HCV coinfection; peginterferon alfa 2a; SVR

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL;

EID: 84858204169     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1301-33     Document Type: Article

References (25)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335-1374.
2. Rockstroh JK, Bhagani S, Benhamou Y et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med. 2008;9: 82-88. (Pubitemid 351228130)
3. Soriano V, Puoti M, Sulkowski M et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007;21:1073-1089. (Pubitemid 46763278)
4. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351:438-450. (Pubitemid 38988593)
5. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839-2848. (Pubitemid 39628231)
6. Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM study abstract 1561. Hepatology. 2009: 50;1022A-501023A
7. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
8. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol. 2007;5:124-129. (Pubitemid 46096836)
9. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol. 2006;62:699-709. (Pubitemid 44749547)
10. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroen-terology. 2007;132:103-112. (Pubitemid 46127673)
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
12. Hadziyannis SJ, Sette H, Jr., Morgan TR, et al. Peginter-feron-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346-355.
13. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451-458.
14. Vogel M, Rockstroh J. Highlights of the third international workshop on HIV and hepatitis coinfection. Expert Rev Anti Infect Ther. 2007;5:769-771. (Pubitemid 47610940)
15. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses. 2007;23:972-982. (Pubitemid 47492337)
16. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroen-terology. 2006;131:470-477. (Pubitemid 44142464)
17. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kD) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology. 2004;39:1702-1708. (Pubitemid 38702672)
18. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265-2271. (Pubitemid 38669209)
19. Rodriguez-Torres M, Jeffers LJ, Sheikh MY et al. Peginter-feron alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009;360:257-267.
20. Jacobson IM, Brown RS, Jr., McCone J et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007;46:982-990. (Pubitemid 350144762)
21. Chung R, Umbleja T, Butt A, et al. SLAM-C (ACTG A5178): Role of early virologic response in extended therapy with PEG-interferon and weight-based ribavirin in HCV/HIV co-infection. Presented at: 16th Conference on Retrovi-ruses and Opportunistic Infections; February 8-11, 2009; Montreal. Abstract 103LB.
22. Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology. 2003;37:1343-1350. (Pubitemid 36667314)
23. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
24. Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepatol. 2006;13: 683-689. (Pubitemid 44401197)
25. Brau N, Rodriguez-Torres M, Prokupek D, et al. Treatment of chronic hepatitis C in HIV/HCV-coinfection with inter-feron alpha-2b+ full-course vs. 16-week delayed ribavirin. Hepatology. 2004;39:989-998. (Pubitemid 38428938)